Abstract: Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

Abstract: [Problem] A pharmaceutical composition for treating or preventing various cardiovascular diseases, which have sGC activities based on improvement of cGMP signals, is provided. [Means for Solution] It was found that imidazo[1,2-a]pyridine compounds having a carbamoyl group at the 3-position and a particular cyclic group at the 8-position via a methyleneoxy group, or a salt thereof have sGC activation, and are useful as active ingredients of pharmaceutical compositions for treating or preventing various sGC-related cardiovascular diseases, in particular, peripheral arterial diseases, intermittent claudication, critical limb ischemia, hypertension, and pulmonary hypertension, thereby completing the present invention.

Abstract: [Problem] A pharmaceutical composition for treating or preventing various cardiovascular diseases, which have sGC activities based on improvement of cGMP signals, is provided. [Means for Solution] It was found that imidazo[1,2-a]pyridine compounds having a carbamoyl group at the 3-position and a particular cyclic group at the 8-position via a methyleneoxy group, or a salt thereof have sGC activation, and are useful as active ingredients of pharmaceutical compositions for treating or preventing various sGC-related cardiovascular diseases, in particular, peripheral arterial diseases, intermittent claudication, critical limb ischemia, hypertension, and pulmonary hypertension, thereby completing the present invention.

Abstract: A compound which can be used as a pharmaceutical, particularly a insulin secretion promoter or a agent for preventing/treating disease in which GPR40 is concerned such as diabetes or the like, is provided. It was found that an oxadiazolidinedione compound which is characterized by the possession of a benzyl or the like substituent binding to the cyclic group via a linker at the 2-position of the oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof, has excellent GPR40 agonist action. In addition, since the oxadiazolidinedione compound of the present invention showed excellent insulin secretion promoting action and blood glucose level-lowering action, it is useful as an insulin secretion promoter or an agent for preventing/treating diabetes.

Abstract: A pharmaceutical agent having GPR40 receptor agonistic action, particularly a compound which is useful as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus. The present inventors have examined a compound having GPR40 receptor agonistic action, confirmed that an oxadiazolidinedione compound which has a substituent such as a benzyl group, etc. linked with a substituent such as a phenyl group, etc. through a linker at the 2-position of an oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof has an excellent GPR40 agonistic activity, and thus completed the invention. The oxadiazolidinedione compound has excellent insulin secretagogue action and anti-hyperglycemic action, and therefore can be used as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus.

Abstract: [Problem] To provide a pharmaceutical, particularly a compound which can be used as an insulin secretion promoter or a preventive or therapeutic agent for diabetes mellitus and the like diseases in which GPR40 is concerned. [Means for resolution] It was found that novel carboxylic acid derivatives or salts thereof, characterized in that carboxylic acid is linked to a 6-membered monocyclic aromatic ring via two atoms and said aromatic ring is linked to a nitrogen-containing bicyclic ring via a linker, have excellent GPR40 receptor agonist action. In addition, since the carboxylic acid derivatives of the invention showed excellent insulin secretion promoting action and blood glucose reducing action, they are useful as an insulin secretion promoter and a preventive or therapeutic agent for diabetes mellitus.

Abstract: [Problem] A compound which can be used as a pharmaceutical, particularly a insulin secretion promoter or a agent for preventing/treating disease in which GPR40 is concerned such as diabetes or the like, is provided. [Means for resolution] It was found that an oxadiazolidinedione compound which is characterized by the possession of a benzyl or the like substituent binding to the cyclic group via a linker at the 2-position of the oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof, has excellent GPR40 agonist action. In addition, since the oxadiazolidinedione compound of the present invention showed excellent insulin secretion promoting action and blood glucose level-lowering action, it is useful as an insulin secretion promoter or an agent for preventing/treating diabetes.

Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt thereof: [wherein X1 and X2 each is independently lower alkylene; X3 is ?CH2, ?CHF or ?CF2; R1 is substituent, R2 and R3 each is independently H or lower alkyl; n is 0, 1, 2, 3 or 4.] having the activity inhibiting DPP-IV activity. They are therefore useful in the treatment of conditions mediated by DPP-IV, such as NIDDM.

Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt thereof: [wherein X1 and X2 each is independently lower alkylene; X3 is ?CH2, ?CHF or ?CF2; R1 is substituent, R2 and R3 each is independently H or lower alkyl; n is 0, 1, 2, 3 or 4.]having the activity inhibiting DPP-IV activity. They are therefore useful in the treatment of conditions mediated by DPP-IV, such as NIDDM.

Abstract: A vulcanizing mold setting apparatus for setting a vulcanizing mold assembly (21) on the platen (6) of a tire vulcanizing apparatus (1) comprises: a mold transfer mechanism (54) comprising a mold carriage (49) for horizontally moving the vulcanizing mold assembly (21) to and away from the tire vulcanizing machine (1), a pair of guide units (41) disposed respectively on the opposite sides of the platen (6), and a pair of mold supporting units (24) disposed respectively on the opposite sides of the platen (6) behind the guide units (41) to support the vulcanizing mold assembly (21) above the platen (6); a pair of lifting mechanisms (27) for vertically moving the mold supporting units (24) to place the vulcanizing mold on the platen (6); a centering mechanism (29) for centering the vulcanizing mold assembly (21) on the platen (6); and clamping members (26) for fastening the fixed mold (7) of the vulcanizing mold assembly (21 ) to the platen (6) after the vulcanizing mold assembly (21) has been centered on the pl

Abstract: A metal printed board having circuit conductors on the surface of an insulating plate layered on a metal plate, wherein grooves formed in the portions of the metal plate which face the circuit conductor. The electronic parts mounted conducts into the metal plate through the solder portions and the insulating plate just thereunder. Accordingly, the presence of the grooves little impairs the thermal conduction. The stray capacitance between the conductor circuit and the metal plate because of the formed grooves, is considerably reduced, so that the signal leakage and noise sneaking are minimized.

Abstract: Double-stem type extrusion method and apparatus used for extrusion-molding rod-like and tubular products. In order to upset a solid or hollow billet (5, 5A) supplied to a container (1), the end of the container (1) which is on the side of a press stem (6) is closed with a blistering-preventing cover (11) which is not moved relatively to the container (1). A pressure is then applied to the billet (5, 5A) from the side of a die (8) to start the yield deformation thereof from the same side thereof. As the yield deformation movement of the billet (5, 5A) progresses, the air existing between the inner surface of the container and billet (5, 5A) is discharged from the portion of the container (1) which is on the side of the cover (11).

Abstract: A die forging press which includes a press machine proper adapted to detachably mount a die set having an upper die and a lower die; an auxiliary station having a die opening mechanism for holding and moving the upper and lower dies of the die set toward and away from each other and a heater having a heating head retractably protrudable to a position between the upper and lower dies when opened by the die opening mechanism. A transfer mechanism for transferring a die set between the press machine and auxiliary station is provided.